These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Dosing regimen of reteplase and costeffectiveness. Hödl R; Kraxner W; Maier R; Klein W Lancet; 2001 Oct; 358(9291):1462. PubMed ID: 11705534 [No Abstract] [Full Text] [Related]
12. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ; J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146 [TBL] [Abstract][Full Text] [Related]
14. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. Kastrati A; Mehilli J; Schlotterbeck K; Dotzer F; Dirschinger J; Schmitt C; Nekolla SG; Seyfarth M; Martinoff S; Markwardt C; Clermont G; Gerbig HW; Leiss J; Schwaiger M; Schömig A; JAMA; 2004 Feb; 291(8):947-54. PubMed ID: 14982910 [TBL] [Abstract][Full Text] [Related]
15. ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy). Cura FA; Roffi M; Pasca N; Wolski KE; Lincoff AM; Topol EJ; Lauer MS; Am J Cardiol; 2004 Oct; 94(7):859-63. PubMed ID: 15464665 [TBL] [Abstract][Full Text] [Related]
17. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation; 2000 Jun; 101(24):2788-94. PubMed ID: 10859283 [TBL] [Abstract][Full Text] [Related]
18. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Coulter SA; Cannon CP; Ault KA; Antman EM; Van de Werf F; Adgey AA; Gibson CM; Giugliano RP; Mascelli MA; Scherer J; Barnathan ES; Braunwald E; Kleiman NS Circulation; 2000 Jun; 101(23):2690-5. PubMed ID: 10851205 [TBL] [Abstract][Full Text] [Related]
19. Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. Nallamothu BK; Bates ER; Hochman JS; Granger CB; Guetta V; Wilcox RG; White HD; Armstrong PW; Savonitto S; Jia G; Lincoff AM; Topol EJ; Eur Heart J; 2005 Aug; 26(15):1506-12. PubMed ID: 15800019 [TBL] [Abstract][Full Text] [Related]
20. Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab. Mukherjee D; Gurm H; Tang WH; Roffi M; Wolski K; Moliterno DJ; Guetta V; Ardissinio D; Bode C; Steg G; Lincoff AM; Topol EJ Am J Cardiol; 2002 Dec; 90(11):1198-203. PubMed ID: 12450598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]